Cargando…

Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study

The introduction of vaccination programs against measles, mumps, and rubella (MMR) led to significant global reduction in morbidity and mortality from these diseases. The currently recommended MMR vaccination schedule in the United States of America comprises 2 vaccine doses typically administered a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abu-Elyazeed, Remon, Jennings, William, Severance, Randall, Noss, Michael, Caplanusi, Adrian, Povey, Michael, Henry, Ouzama
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314414/ https://www.ncbi.nlm.nih.gov/pubmed/29902133 http://dx.doi.org/10.1080/21645515.2018.1489186

Ejemplares similares

Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines
por: Habib, Md Ahsan, et al.
Publicado: (2023)

Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study
por: Klein, Nicola P, et al.
Publicado: (2019)

Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore: A phase II, randomized, double-blind trial
por: Huang, Li-Min, et al.
Publicado: (2013)

Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine: an open-labeled, randomized trial in healthy Korean children
por: Cha, Sung-Ho, et al.
Publicado: (2014)

Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin
por: Berry, Andrea A., et al.
Publicado: (2017)

571. A Report of the Postmarketing Spontaneous Safety Data over 24 Years for GSK’s Measles-Mumps-Rubella (MMR) Vaccine
por: Singh, Tina, et al.
Publicado: (2022)

Difficulties in Eliminating Measles and Controlling Rubella and Mumps: A Cross-Sectional Study of a First Measles and Rubella Vaccination and a Second Measles, Mumps, and Rubella Vaccination
por: Wang, Zhifang, et al.
Publicado: (2014)

Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial
por: Lalwani, Sanjay, et al.
Publicado: (2015)

Knowledge and Practice of Parents Towards Measles, Mumps and Rubella Vaccination
por: Hussein, Siti Zuhaida, et al.
Publicado: (2022)

Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study
por: dos Santos, Eliane Matos, et al.
Publicado: (2019)

Measles, Mumps, Rubella serology in juvenile idiopathic arthritis
por: Heijstek, MW, et al.
Publicado: (2008)

Is it time to reconsider measles, mumps, and rubella immunisation strategies?
por: Boccalini, Sara, et al.
Publicado: (2021)

Measles-Mumps-Rubella Vaccine and COVID-19 Relationship
por: Özdemir, Öner
Publicado: (2020)

Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis
por: Schenk, Julie, et al.
Publicado: (2021)

Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant
por: Desjardins, Michaël, et al.
Publicado: (2021)

2467. Timeliness of Childhood Vaccination With the Combination Measles–Mumps–Rubella–Varicella Vaccine vs. the Separate Measles–Mumps–Rubella and Varicella Vaccines in the United States
por: Wolfson, Lara, et al.
Publicado: (2018)

Measles, rubella, mumps and chicken pox seroprevalence of health workers in a second level hospital
por: Guerrero Fernández de Alba, I, et al.
Publicado: (2022)

Resurgence risk for measles, mumps and rubella in France in 2018 and 2020
por: Béraud, Guillaume, et al.
Publicado: (2018)

Utility of serological screening for measles, mumps and rubella in immunocompromised patients
por: Sticchi, L, et al.
Publicado: (2019)

Inadequate Measles, Mumps, Rubella, and Varicella Immunity Among Employees
por: Ezeji-Okoye, Stephen, et al.
Publicado: (2021)

An Economic Analysis of Mumps Vaccination in Fiji: Static Model Simulation of Routine Measles–Mumps–Rubella (MMR) Vaccination Instead of Current Measles–Rubella (MR) Vaccination
por: Oh, Chunghyeon, et al.
Publicado: (2022)

1339 Measles and Mumps Antibody Response in Young Adults after a Third Dose of Measles-Mumps-Rubella Vaccine
por: Fiebelkorn, Amy Parker, et al.
Publicado: (2014)

Immunogenicity of measles-rubella vaccine administered under India’s Universal Immunization Programme in the context of measles–rubella elimination goal: A longitudinal study
por: Verma, Santosh Kumar, et al.
Publicado: (2023)

Measles, Mumps, and Rubella Antibody: Patterns of Persistence and Rate of Decline Following the Second Dose of the MMR Vaccine
por: Seagle, Emma, et al.
Publicado: (2017)

Partial third nerve palsy after Measles Mumps Rubella vaccination
por: Manzotti, Francesca, et al.
Publicado: (2010)

Efficacy of intralesional injection of mumps-measles-rubella vaccine in patients with wart
por: Zamanian, Abbas, et al.
Publicado: (2014)

Perspectives on the Measles, Mumps and Rubella Vaccination among Somali Mothers in Stockholm
por: Jama, Asha, et al.
Publicado: (2018)

Reply to Özdemir, “Measles-Mumps-Rubella Vaccine and COVID-19 Relationship”
por: Fidel, Paul L., et al.
Publicado: (2020)

Measles-mumps-and-rubella-virus-vaccine: Aseptic meningitis: case report
Publicado: (2021)

Measles mumps and rubella virus vaccine: Various toxicities: case report
Publicado: (2022)

Response to Measles, Mumps and Rubella (MMR) Vaccine in Transfusion-Dependent Patients
por: Casale, Maddalena, et al.
Publicado: (2021)

Buschke–Lowenstein tumor treated with intralesional measles, mumps, and rubella vaccine
por: Deshmukh, Ashish, et al.
Publicado: (2022)

Mumps Antibody Response in Young Adults After a Third Dose of Measles-Mumps-Rubella Vaccine
por: Fiebelkorn, Amy Parker, et al.
Publicado: (2014)

Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety
por: Ma, Shu-Juan, et al.
Publicado: (2015)

Measles–mumps–rubella vaccination and respiratory syncytial virus-associated hospital contact
por: Sørup, Signe, et al.
Publicado: (2015)

Seroprevalences of Specific IgG Antibodies to Measles, Mumps, and Rubella in Korean Infants
por: Cho, Hye-Kyung, et al.
Publicado: (2016)

Prevalence of Inadequate Immunity to Measles, Mumps, Rubella, and Varicella in MLB and NBA Athletes
por: Conway, Justin J., et al.
Publicado: (2018)

Comparison of Intralesional Measles, Mumps, Rubella Vaccine and Needling in the Treatment of Recurrent Warts
por: Kolte, Surabhi R., et al.
Publicado: (2020)

Safety of measles, mumps, and rubella vaccine in egg allergy: in vivo and in vitro management
por: Magistà, Stefania, et al.
Publicado: (2020)

1209. Seroprevalence of Measles, Mumps, and Rubella in Korean Healthcare Workers and Strategy for Vaccination
por: Ju Choo, Eun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bb4san755lpvufgjcp7ipcplam